- Home
- NBIX vs REG Comparison
NBIX vs REG Comparison
Compare NBIX & REG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- REG
- Stock Information
- Founded
- NBIX 1992
- REG 1963
- Country
- NBIX United States
- REG United States
- Employees
- NBIX N/A
- REG N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- REG Real Estate Investment Trusts
- Sector
- NBIX Health Care
- REG Real Estate
- Exchange
- NBIX Nasdaq
- REG Nasdaq
- Market Cap
- NBIX 12.2B
- REG 12.9B
- IPO Year
- NBIX 1996
- REG 1993
- Fundamental
- Price
- NBIX $126.55
- REG $71.14
- Analyst Decision
- NBIX Strong Buy
- REG Buy
- Analyst Count
- NBIX 20
- REG 12
- Target Price
- NBIX $163.20
- REG $78.08
- AVG Volume (30 Days)
- NBIX 971.0K
- REG 1.1M
- Earning Date
- NBIX 07-31-2025
- REG 07-31-2025
- Dividend Yield
- NBIX N/A
- REG 3.96%
- EPS Growth
- NBIX N/A
- REG 2.69
- EPS
- NBIX 2.96
- REG 2.11
- Revenue
- NBIX $2,412,600,000.00
- REG $1,522,885,000.00
- Revenue This Year
- NBIX $16.29
- REG $1.44
- Revenue Next Year
- NBIX $15.08
- REG $4.13
- P/E Ratio
- NBIX $42.79
- REG $33.73
- Revenue Growth
- NBIX 21.73
- REG 7.57
- 52 Week Low
- NBIX $84.23
- REG $60.64
- 52 Week High
- NBIX $157.98
- REG $78.18
- Technical
- Relative Strength Index (RSI)
- NBIX 64.01
- REG 47.56
- Support Level
- NBIX $122.66
- REG $69.80
- Resistance Level
- NBIX $126.00
- REG $73.03
- Average True Range (ATR)
- NBIX 2.55
- REG 1.07
- MACD
- NBIX -0.33
- REG -0.11
- Stochastic Oscillator
- NBIX 72.06
- REG 42.38
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About REG Regency Centers Corporation
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 482 properties, which includes nearly 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.